Innovative Immunology Biotech Windward Bio Lists on Nasdaq

• Windward Bio (WWB) IPO'd on Nasdaq Nov 13, 2026 at $17/share, closing up 68% at $28.50, ~$1.69B market cap. • Qiming Venture Partners backed Windward since its 2025 Series A; this is Qiming's 11th IPO in 2026. • Windward develops long-acting antibodies (WIN378, WIN027) for asthma, COPD, and atopic dermatitis. Windward Bio (Nasdaq: WWB), a clinical-stage biotech backed by Qiming Venture Partners, listed on Nasdaq on November 13, 2026. Its IPO priced at $17.00 per share, and shares closed the first day at $28.50, up 68%, giving the company a market cap of roughly $1.69 billion. This marks Qiming's 11th IPO of 2026. Qiming first invested in Windward's 2025 Series A and continued through its Series B and this IPO. Founded in 2024, Windward develops ultra-long-acting antibody therapies for chronic inflammatory diseases, including asthma, COPD, and atopic dermatitis. Its lead candidate, WIN378, an anti-TSLP monoclonal antibody, is in Phase 2/3 trials for severe asthma (POLARIS-1) and Phase 2 for COPD (SIRIUS), licensed globally (excluding Greater China and parts of Asia) from Kelun-Biotech and Harbour BioMed. Its pipeline also includes WIN027, a bispecific antibody targeting TSLP and IL-13, licensed from Qyuns Therapeutics. Qiming's Alexander Sinclair Wilson said the firm believes these long-acting biologics could reshape treatment of severe respiratory and skin diseases. Founded in 2006, Qiming manages $9.5 billion across 18 funds and has backed over 630 companies, with 290+ exits via IPO or M&A and 110+ unicorns.